Akouos, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals

Indianapolis , dec. 1, 2022 /prnewswire/ -- eli lilly and company (nyse: lly) today announced the successful completion of its acquisition of akouos, inc. (nasdaq: akus). the acquisition expands lilly's efforts in genetic medicines to include akouos's portfolio of potential first-in-class adeno-associated viral gene therapies for the treatment of inner ear conditions, including sensorineural hearing loss.

Indianapolis and boston , nov. 30, 2022 /prnewswire/ -- eli lilly and company (nyse: lly) and akouos, inc. (nasdaq: akus) today announced that the tender offer to purchase all of the issued and outstanding shares ("shares") of akouos's common stock in exchange for (a) $12.50 per share, net to the stockholder in cash, without interest and less any applicable tax withholding, plus (b) one non-tradable contingent value right ("cvr") per share, which represents the contractual right to receive contingent payments of up to $3.00 per cvr, net to the stockholder in cash, without interest and less any applicable tax withholding, upon the achievement of certain specified milestones (the "offer"), expired as scheduled at one minute past 11:59 p...

New york , oct. 21, 2022 /prnewswire/ -- weiss law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of akouos, inc. ("akouos" or the "company") (nasdaq: akus), in connection with the proposed tender offer for the company by eli lilly and company (nyse: lly).  under the tender offer, the company's shareholders will receive $12.50 in cash, plus one contingent value right ("cvr") of up to $3.00 per share for each share of akouos common stock owned.

New orleans--(business wire)--former attorney general of louisiana charles c.

Proposed acquisition will accelerate gene therapies that aim to restore, improve, and preserve hearing for patients living with disabling hearing loss worldwide transaction valued at approximately $487 million plus a contingent value right for an aggregate amount up to approximately $610 million indianapolis and boston , oct. 18, 2022 /prnewswire/ -- eli lilly and company (nyse: lly) and akouos, inc. (nasdaq: akus) today announced a definitive agreement for lilly to acquire akouos, a precision genetic medicine company that is developing a portfolio of first-in-class adeno-associated viral gene therapies for the treatment of inner ear conditions, including sensorineural hearing loss. "we are honored to work with the talented team at akouos who are breaking new ground in the science of treating hearing loss," said andrew c.

There's notable merger news today as pharmaceutical giant Eli Lilly (NYSE: LLY ) entered into a definitive agreement to acquire Akouos (NASDAQ: AKUS ). Clearly, Eli Lilly is looking to expand further into gene therapies.

A buyout agreement is lighting a fire underneath the biotech's shares today.

Drugmaker Eli Lilly and Co will acquire genetic medicine developer Akouos Inc in a cash deal worth about $487 million.

Eli Lilly and Co. LLY, +0.41% said Tuesday it has entered an agreement to acquire Akouos Inc. AKUS, -5.14% , a company developing a portfolio of viral gene therapies for the treatment of inner ear conditions including hearing loss, for up to $610 million in cash. Under the terms of the deal, Akouos shareholders will receive $12.50 a share in cash, plus one non-tradeable contingent value right per share that entitles the holder to receive up to an additional $3.00 in cash, for a total consideration of up to $15.50 per share in cash without interest, or an aggregate of $610 million.

Akouos, Inc. (AKUS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Akouos, Inc. (AKUS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

BOSTON, May 04, 2022 (GLOBE NEWSWIRE) -- Akouos, Inc. (“Akouos”) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced that Manny Simons, Ph.D., M.B.A., co-founder, president, and chief executive officer of Akouos, will participate in a presentation at the Bank of America 2022 Healthcare Conference on Tuesday, May 10 at 10:00 a.m. PDT in Las Vegas, Nevada.

BOSTON, March 24, 2022 (GLOBE NEWSWIRE) -- Akouos, Inc. (“Akouos”) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced that Manny Simons, Ph.D., M.B.A., co-founder, president, and chief executive officer will participate in two upcoming virtual investor conferences in March:

BOSTON, Jan. 07, 2022 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced that new nonclinical data will be presented at the Association for Research in Otolaryngology (ARO) 45th Annual Mid-Winter Meeting, which is being held in San Jose, California from February 5 to 9, 2022.

BOSTON, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Akouos, Inc. (“Akouos”) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced that Manny Simons, Ph.D., M.B.A., co-founder, president, and chief executive officer of Akouos, will participate in a presentation at the Jefferies Gene Therapy/Editing Summit on Wednesday, October 27 at 9:30 a.m. EDT.